Vepdegestrant in ESR1-Mutant Breast Cancer | New England Journal of ...
FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative ...
Oral Breast Cancer Drug Wins Broader FDA Nod for ESR1-Mutated Disease ...
MSK Discovery of ESR1 Gene Mutation Leads to Approval of Breast Cancer ...
FDA Greenlights First Drug for ESR1-Mutated Breast Cancer | MedPage Today
Detection of Ultra-Rare ESR1 Mutations in Primary Breast Cancer Using ...
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review ...
Guardant Health receives FDA approval for Guardant360® CDx as companion ...
FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer
Frontiers | A review of FDA approved drugs and their formulations for ...
A roadmap for accelerated drug approval in breast cancer? - The Lancet ...
RA Approval for Breast Cancer Study Received
Inluriyo: FDA Approves New Once-Daily Pill for ESR1-Mutated Advanced ...
Influence of Estrogen Treatment on ESR1+ and ESR1− Cells in ER+ Breast ...
US Food and Drug Administration Approval Summary: Elacestrant for ...
ESR1 mutations—a mechanism for acquired endocrine resistance in breast ...
Eli Lilly's Inluriyo: A Breakthrough Oral Treatment for Advanced Breast ...
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant ...
Testing for ESR1 Mutations Recommended in HR+, HER2- Metastatic Breast ...
Frontiers | Validation of liquid biopsy for ESR1-mutation analysis in ...
Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer
AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast ...
Genomic modelling of the ESR1 Y537S mutation for evaluating function ...
Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast ...
Tailoring Potential Natural Compounds for the Treatment of Luminal ...
Blockbuster drug lands first-line indication for HER2-positive breast ...
Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
RxTROSPECT — FDA has approved Enhertu for patients with the HER2-low ...
FDA Approves Isatuximab With VRd as First-Line Option for Transplant ...
FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced ...
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast ...
How new Insights into ESR1 Mutant Breast Cancers may lead to Novel ...
Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated ...
Second in line for ESR1-mutant patients | ApexOnco - Clinical Trials ...
ESR1-Mutated Metastatic Breast Cancer Market to Climb Swiftly at a ...
Imlunestrant Good for ER+, HER2− Breast Cancer With ESR1 Mutations
ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A ...
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of ...
ESR1 alterations and metastasis in estrogen receptor positive breast cancer
Vepdegestrant Bests Fulvestrant in ER+/HER2-, ESR1-Mutant Advanced ...
RON signalling promotes therapeutic resistance in ESR1 mutant breast ...
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast ...
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ...
Frontiers | Clinical Implications of ESR1 Mutations in Hormone Receptor ...
Frontiers | Detection of ESR1 Mutations Based on Liquid Biopsy in ...
Elacestrant Monotherapy as a Second-Line Treatment for ER-Positive ...
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive ...
Currently Applied Molecular Assays for Identifying ESR1 Mutations in ...
Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next ...
Frontiers | ESR1 Mutations Are Not a Common Mechanism of Endocrine ...
Imlunestrant approved for ER+, HER2-, ESR1-mutated advanced or ...
Frontiers | Epigenetic modulation of antitumor immunity and ...
Recent Advances in the Treatment of Breast Cancer. - Abstract - Europe PMC
Launch of White Paper on ESR1 Mutation and Liquid Biopsy in Metastatic ...
The Changing Landscape of Breast Cancer: How Biology Drives Therapy
Enhertu reduced the risk of disease recurrence or death by 53% vs. T ...
ESR1 mutant breast cancers show elevated basal cytokeratins and immune ...
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast ...
ESR1 Mutations in Breast Cancer - PMC
Targeting ESR1 mutation–induced transcriptional addiction in breast ...
Exploring the role of ESR1 mutations in metastatic hormone receptor ...
The EstroGene2.0 database for endocrine therapy response and resistance ...
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1 ...
Identifying ESR1 Mutations to Determine Resistance in HR+ Metastatic ...
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance ...
Endocrine-therapy-resistant ESR1 variants revealed by genomic ...
ESR1 Mutations in Breast Cancer: What They Mean and Treatment
Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist ...
Frontiers | ESR1 fusions and therapeutic resistance in metastatic ...
Giredestrant reverses progesterone hypersensitivity driven by estrogen ...
Estrogen-Receptor Loss and ESR1 Mutation in Estrogen-Receptor-Positive ...
ESR1 mutations affect anti-proliferative responses to tamoxifen through ...
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor ...
Correction: RON signalling promotes therapeutic resistance in ESR1 ...
Vaccines targeting ESR1 activating mutations elicit anti-tumor immune ...
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression ...
Pure estrogen receptor antagonists potentiate capecitabine activity in ...
Plasma ESR1 mutations and outcome to first-line paclitaxel and ...
Imlunestrant a next-generation oral SERD overcomes ESR1 mutant ...
GT-Plex™ ESR1 Panel - GT Molecular
slide5
Science Hub
Our Pipeline: Potential Breakthroughs in the Making
slide9
ZeptoMetrix Diagnostic White Papers | Clinical & Lab Insights
70367-4/asset/1493b7c8-22d8-477e-8c9f-c93c33aae5b9/main.assets/fx1.jpg)
